Pharmacogenetics of risperidone: A systematic review of the clinical effects of CYP2D6 polymorphisms;Farmacogenética de la risperidona: Una revisión sistemática de los efectos clínicos de los polimorfismos del CYP2D6

Annals of Pharmacotherapy

Volumn 47, Issue 3, 2013, Pages 350-360

  Cartwright, Andrea L ^a   Wilby, Kyle J ^b   Corrigan, Susan ^a,c   Ensom, Mary H H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Qatar University ^*  (Qatar)

^c SURREY MEMORIAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYTOCHROME P450 2D6; OLANZAPINE; RISPERIDONE;

ABSENCE OF SIDE EFFECTS; ARTICLE; AUTISM; BIPOLAR DISORDER; BODY MASS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; LOW DRUG DOSE; PARKINSON DISEASE; PHARMACOGENETICS; PHENOTYPE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QT PROLONGATION; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; HUMANS; POLYMORPHISM, GENETIC; RISPERIDONE; TREATMENT OUTCOME;

EID: 84875167094     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R333     Document Type: Article

References (39)

1. Product monograph. Risperdal (risperidone tablets). Toronto, ON: Janssen Inc., September 2011. www.janssen.ca/subcategory_docdownload?id=599 (accessed 2012 May 15).
2. Gardner DM, Badessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2004;172:1703-11.
3. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009;48:761-804.
4. De Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010;51:80-8.
5. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch Pharmacol 2004;369:23-37.
6. MedlinePlus medical dictionary. 2012. http://www.nlm.nih.gov/medlineplus/mplusdictionary.html (accessed 2012 Aug 27).
7. TheFreeDictionary. 2012. http://medical-dictionary.thefreedictionary.com/(accessed 2012 Aug 27).
8. Chou W-H, Yan F-X, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003;49:542-51.
9. Kato D, Kawanishi C, Kishida I, et al. Delirium resolving upon switching from risperidone to quetiapine: implication of CYP2D6 genotype. Psychosomatics 2005;46:374-5.
10. Kohnke MD, Griese EU, Stosser D, et al. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002;35:116-8.
11. Llerena A, Berecz R, Dorada P, et al. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J Chromatogr B 2003;783:213-9.
12. Ochi S, Kawasoe K, Abe M, et al. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. Gen Hosp Psychiatry 2011;33:640. e1-e2.
13. Kay SR, Flszbein A, Opfer LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizo Bull 1987;13:261-76.
14. Kakihara S, Yoshimura R, Shinkai K, et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005;20:71-8.
15. Riedel M, Schwarz MJ, Strassnig M, et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005;255:261-8.
16. Jovanovic N, Bozina N, Lovric M, Medved V, Jakovljevi M, Peles AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 2010;66:1109-17.
17. Bartecek R, Jurica J, Zrustova J, Kasparek T, Pindurova E, Zourkova A. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuroendocrinol Lett 2012;33:236-44.
18. Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999;60:469-76.
19. Llerena A, Berecz R, Dorado P, de la Rubia A. QTc Interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 2004;18:189-93.
20. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
21. Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006;26:128-34.
22. Novalbos J, Lopex-Rodriguez R, Roman M, Gallego-Sandin S, Ochoa D, Abad-Santos F. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol 2010;30:504-11.
23. Troost PW, Lahuis BE, Hermans MH, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007;27:52-7.
24. Correia CT, Almeida JP, Santos PE, et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 2010;10:418-30.
25. US Preventive Services Task Force. Guide to clinical preventive services: report of the US Preventive Services Task Force. 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins, 1996.
26. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
27. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005;25:448-56.
28. Müller DJ, Brandl EJ, Hwang R, et al. The amplichip CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study. Genet Test Mol Biomarkers 2012;16:1-7.
29. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45:11-9.
30. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res 2005;79:231-8.
31. AmpliChip CYP450 Test. Roche Molecular Diagnostics. http://molecular. roche.com/assays/Pages/AmpliChipCYP450Test.aspx (accessed 2012 Jul 27).
32. Roche AmpliChip CYP450 Test and Affymetrix GeneChip System 3000Dx. The Pharmacogenomics Knowledge Base [PharmGKB]. http://www.pharmgkb. org/Load/geneticTest.action?id=769180190 (accessed 2012 Jul 27).
33. Schroth W, Hamann U, Fasching PA, et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 2010;16:4468-77.
34. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011;25:933-69.
35. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006;58:871-85.
36. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia (CATIE). N Engl J Med 2005;353:1209-23.
37. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomized antipsychotic drug trials. Psychopharmacology 2001;155:230-3.
38. Tiihonen J, Walhbeck K, Lonngvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333:224. doi: 10.1136/bmj.38881.382755.2F
39. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatr Res 2010;176:109-13.